COMMUNIQUÉS West-GlobeNewswire

Novo Nordisk A/S - Share repurchase programme
13/06/2017
Bagsværd, Denmark, 13 June 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
Midatech Pharma Plc: R&D manufacturing site visit for investors and analysts
13/06/2017
13 June 2017 Midatech Pharma PLC ("Midatech", "Company" or "Group") R&D manufacturing site visit for investors and analysts Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical [...]
Summit Therapeutics plc : Notice of Results
13/06/2017
Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS TO REPORT FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 30 APRIL 2017 ON 14 JUNE 2017 Oxford, UK, 13 June 2017 - Summit Therapeutics plc (AIM: SUMM [...]
Acarix Receives First Commercial Order For CADScor®System For Early Detection Of Coronary Artery Disease From Danish Hospital
13/06/2017
Press release Malmö, June 13, 2017 Acarix Receives First Commercial Order For CADScor ® System For Early Detection Of Coronary Artery Disease From Danish Hospital Commercialization program on track Acarix AB (publ) (" [...]
Silmäasema Oyj: Managers' Transactions - Kaisa Vikkula
13/06/2017
Silmäasema Oyj - Managers' Transactions Kaisa Vikkula 13 June 2017, at 11.00 a.m. ____________________________________________ Person subject to the notification requirement Name: Vikkula, Kaisa Position: Member of the [...]
Silmäasema Oyj: Managers' Transactions - Anu Kankkunen
13/06/2017
Silmäasema Oyj - Managers' Transactions Anu Kankkunen 13 June 2017, at 11 a.m. ____________________________________________ Person subject to the notification requirement Name: Kankkunen, Anu Marjut Position: CFO Issuer [...]
Silmäasema Oyj: Managers' Transactions - Torsti Sihvola
13/06/2017
Silmäasema Oyj - Managers' Transactions Torsti Sihvola 13 June 2017, at 11.00 a.m. ____________________________________________ Person subject to the notification requirement Name: Sihvola, Torsti Position: Member of [...]
FIT Biotech Oy: FIT Biotech Oy's Board of Directors has decided on the issue of Convertible Notes and Warrants
13/06/2017
FIT Biotech Oy Company release June 13, 2017 at 10:00 am FIT Biotech Oy's Board of Directors has decided on the issue of Convertible Notes and Warrants On September 26, 2016, the Board of Directors of FIT Biotech Oy ( [...]
Basilea awarded USD 54.8 million of additional funding by BARDA to support phase 3 development of ceftobiprole
13/06/2017
Basel, Switzerland, June 13, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has been awarded USD 54.8 million for two additional options on its existing contract with the Biomedical Advanced [...]
Biocartis Group NV: Disclosure of a transparency notification
13/06/2017
PRESS RELEASE: REGULATED INFORMATION 13 June 2017, 07:01 CEST Disclosure of a transparency notification (Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings) Mechelen, Belgium, [...]
ABLYNX APPOINTS MARKUS EWERT AS CHIEF BUSINESS OFFICER
13/06/2017
GHENT, Belgium, 13 June 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced the appointment of Markus L.E. Ewert, PhD, MBA, as Chief Business Officer (CBO). Effective from 20 June 2017, Dr Ewert will [...]
argenx to Present at JMP Securities Life Sciences Conference
13/06/2017
June 13, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the [...]
Biocartis Group NV: Biocartis launches CE-marked IVD test for lung cancer
13/06/2017
PRESS RELEASE: 13 June 2017, 07:00 CEST Biocartis launches CE-marked IVD test for lung cancer Idylla(TM) EGFR Mutation Test is the only on market fully automated CE-IVD test detecting all relevant EGFR mutations [...]
TiGenix Launches Global Phase III Trial for Cx601
13/06/2017
PRESS RELEASE TiGenix Launches Global Phase III Trial for Cx601 Leuven (BELGIUM) - June 13, 2017, 07:00h CEST - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting [...]
Tresiba® demonstrated no increased risk of major cardiovascular events and significant reduction in rates of severe hypoglycaemia compared to insulin glargine U100 in the DEVOTE trial
12/06/2017
San Diego, US, 12 June 2017 - Novo Nordisk today announced the primary results from DEVOTE - the first randomised, double-blind, treat-to-target, event-driven trial comparing two basal insulins, Tresiba ® (insulin [...]
ProLynx présente PLX039, un système d'administration de médicament sous forme de microsphères d'hydrogel impliquant la prise mensuelle unique d'un agoniste de récepteur GLP 1
12/06/2017
SAN FRANCISCO, le 12 juin 2017 (GLOBE NEWSWIRE) - Dans un abrégé de dernière minute, lors du 77 e congrès de l'American Diabetes Association à San Diego, ProLynx LLC a présenté un nouveau système d'administration de [...]
Silmäasema Oyj: Announcement of a change in shareholding according to Chapter 9, Section 10 of the Finnish Securities Market Act
12/06/2017
Silmäasema Oyj: Announcement of a change in shareholding according to Chapter 9, Section 10 of the Finnish Securities Market Act Stock Exchange Release 12 June 2017, at 9.15 p.m. Silmäasema Oyj (the "Company") has today [...]
XBiotech annonce l'interruption de l'étude de phase III pour le cancer colorectal sur la base de la deuxième analyse intermédiaire
12/06/2017
AUSTIN, Texas, le 9 juin 2017 (GLOBE NEWSWIRE) - XBiotech Inc. (NASDAQ:XBIT) a annoncé aujourd'hui qu'un Comité indépendant de surveillance et de suivi des données (IDMC) a réalisé une analyse prospective sans insu de l [...]
Ossur Hf : Transactions in relation to share buyback program
12/06/2017
Announcement from Össur hf. No. 44/2017 Reykjavík, 12 June 2017 On 1 December 2016, Össur hf. initiated a new share buy-back program, see Company announcement no. 96/2016. The purpose of the share buyback program is to [...]

Pages